Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Des Moines, Iowa

Cancer surgery and procedure trials in Des Moines, IA

41 cancer surgery and procedure studies are recruiting participants at sites in Des Moines as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Des Moines at a glance

  • 41 studies are recruiting at a site in Des Moines.
  • By phase: Phase 1/2 (1), Phase 2 (15), Phase 3 (23), Observational (2).
  • By sponsor: university, hospital or other (22), government (19).
  • By research area: Lymphoma (14), Lung Cancer (10), Breast Cancer (8), Pancreatic Cancer (5), Prostate Cancer (3), Melanoma (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Des Moines

Basic details from each study's public record (the 30 most recently updated of 41). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Medical Center - Des Moines · UI Health Care Mission Cancer and Blood - Des Moines Clinic · UI Health Care Mission Cancer and Blood - Laurel Clinic
    Registry record
    NCT05564377 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT07391774 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT06058377 · updated
  4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Iowa Methodist Medical Center · Mercy Medical Center - Des Moines · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT05334069 · updated
  5. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT07578116 · updated
  6. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Des Moines, IA on ClinicalTrials.gov.

Lung cancer studies recruiting in Des Moines

  1. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT04665739 · updated
  2. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT06498635 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Iowa Methodist Medical Center · Mercy Medical Center - Des Moines · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT06096844 · updated
  5. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT04181060 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic · UI Health Care Mission Cancer and Blood - Laurel Clinic
    Registry record
    NCT06031688 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Des Moines, IA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Des Moines

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Iowa Methodist Medical Center · Mercy Medical Center - Des Moines · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT03866382 · updated
  2. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Iowa Methodist Medical Center
    Registry record
    NCT07200830 · updated
  3. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    SWOG Cancer Research Network
    Study site
    Iowa Methodist Medical Center
    Registry record
    NCT03678025 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Des Moines, IA on ClinicalTrials.gov.

Melanoma studies recruiting in Des Moines

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Medical Center - Des Moines · UI Health Care Mission Cancer and Blood - Des Moines Clinic · UI Health Care Mission Cancer and Blood - Laurel Clinic
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Des Moines, IA on ClinicalTrials.gov.

Lymphoma studies recruiting in Des Moines

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UI Health Care Mission Cancer and Blood - Des Moines Clinic · UI Health Care Mission Cancer and Blood - Laurel Clinic
    Registry record
    NCT03739814 · updated
  2. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Blank Children's Hospital
    Registry record
    NCT06317662 · updated
  3. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic · UI Health Care Mission Cancer and Blood - Laurel Clinic
    Registry record
    NCT06337318 · updated
  4. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Blank Children's Hospital
    Registry record
    NCT04726241 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Blank Children's Hospital
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Blank Children's Hospital · Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT05675410 · updated
  8. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Registry record
    NCT06649812 · updated
  9. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT05976763 · updated
  10. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT07215910 · updated
  11. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT07321652 · updated
  12. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Mercy Medical Center - Des Moines
    Registry record
    NCT05890352 · updated
  13. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Blank Children's Hospital
    Registry record
    NCT06124157 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Des Moines, IA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Des Moines

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Broadlawns Medical Center · Iowa Methodist Medical Center · Mercy Medical Center - Des Moines
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Des Moines, IA on ClinicalTrials.gov.

Ask about studies near Des Moines

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call